Your characterization is so on target...in the mind of the collective FDA...bigger is better...and largely that would be true...a bigger universe of data should provide a better estimate of what average looks like...but smaller trials with above-average results should be seen as a gateway/gaslight on results and should be considered... as you've noted, especially in the pandemic world...we currently find ourselves.